CAP-1002: Phase I/II ongoing

Capricor dosed the last of 134 patients who suffered an MI resulting in scar tissue accompanied by cardiac dysfunction in the Phase II portion of the double-blind, placebo-controlled, North American Phase I/II ALLSTAR trial evaluating single intracoronary infusions of CAP-1002. Capricor is partnered with Johnson & Johnson’s Janssen Biotech Inc. unit to develop Capricor’s cell therapy programs for cardiologic applications, including CAP-1002 (see BioCentury, Jan. 13, 2014). ...